News

PRAC September 2024 – Recommendation for metamizole and to minimise the risk associated with medroxyprogesterone acetate

The PRAC recommends measures to minimise serious outcomes of known side effect with the painkiller metamizole and formulated new recommendations to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate. During its September 2024 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended measures to minimise serious outcomes of known side effect with painkiller metamizole and formulated new recommendations to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate.

Limited availability of Zypadhera powder and solvent for suspension with prolonged release used for injections: recommendations update

Because of a delay in the planned deliveries of the Zypadhera medicinal product (intramuscular (IM) olanzapine with prolonged disease) by the Cheplapharm Registration company, supplies in Belgium are limited. The availability of these medicinal products is also limited in other European countries. Therefore, the experts of the Unavailability Task Force update the previous recommendations.

Flash VIG-news: Benzodiazepine withdrawal programme extended until 31 December 2024

Since 1 February 2023, a withdrawal programme can be provided for outpatients taking benzodiazepines or Z-drugs. This programme is based on the magistral preparation of capsules following a doctor's prescription. The project, which was initially due to run for one year, has been extended until 31 December 2024.

Warning: serious adverse reactions when administering the veterinary medicinal product Senvelgo (velagliflozin molecule) to cats suffering from diabetes

The Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA), having analysed recent reports on diabetic ketoacidosis associated with Senvelgo use, now issues recommendations.

PRAC July 2024 – New recommendations for GLP-1 receptor agonists and direct healthcare professional communication for glatiramer acetate containing products

During its July 2024 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency issued new recommendations for GLP-1 receptor agonists and agreed a direct healthcare professional communication for glatiramer acetate containing products.